MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: www.youtube.com/msviewsandnews -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Thursday, October 27, 2016

More to know of OCREVUS (Ocrelizumab),


                                                                  
  

Click here to receive MS news via e-mail



OCREVUS (generic name Ocrelizumab) is a humanized monoclonal antibody under clinical investigation and development by the Swiss pharmaceutical company Roche as a potential treatment for people with multiple sclerosis (MS). The therapy is targeted against mature B-lymphocytes with CD20 markers on their surface, giving the drug an immunosuppressive function that might reduce the rates of immune system attacks on its own myelinated neurons, the main pathogenesis in the disease. OCREVUS is not yet an approved therapy, but it has shown promise in treating both relapsing forms of multiple sclerosisand primary progressive multiple sclerosis, a disease form with no approved treatments to date.

How Ocrelizumab Works

Ocrelizumab, an anti-CD20 monoclonal antibody, targets mature B-cells. Almost 95 percent of the B-cell population has these antigenic epitopes after maturation and does not shed them, which is what makes it a potent marker for therapeutic purposes. It is believed that these CD20-positive B-cells target axons and myelin sheaths of healthy neurons, initiating a cascading series of immune reactions that lead to MS and disability in patients. Preclinical studies have shown that ocrelizumab binds to specific B-cells with CD20 markers but not to stem cells and plasma cells, preserving vital immune functions within the host.


MS Views and News
Providing educational information, resources and services for those affected by MS



No comments: